S11 Ep8: Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC

OncLive® On Air - A podcast by OncLive® On Air

Podcast artwork

Dr Salgia discusses how he chooses between tepotinib and capmatinib in patients with stage IV NSCLC harboring MET exon 14 skipping mutations.